Kentera (Oxybutynin)

• Kentera (oxybutynin) acts on the urinary bladder's smooth muscle to reduce involuntary contractions.
• Overactive bladder: reduces the frequency of urgency episodes, increases functional bladder capacity, and improves overall urinary storage symptoms.
• Urinary urgency: lessens the sudden urge to void, allowing patients to delay micturition and maintain better daily activities.
• Urge urinary incontinence: decreases episodes of involuntary leakage, supports continence during physical activity, and enhances quality of life.
• Neurological bladder overactivity: helps manage urinary symptoms in patients with spinal cord injury or multiple sclerosis, improving bladder control.

• Oxybutynin is an antimuscarinic agent that competitively blocks muscarinic M3 receptors on detrusor smooth muscle in the bladder. By inhibiting acetylcholine binding, it reduces involuntary detrusor contractions, thereby increasing bladder capacity and decreasing urgency and urge incontinence. The transdermal delivery system provides steady systemic absorption, avoiding first‑pass metabolism. Its lipophilic properties enable efficient skin permeation, maintaining therapeutic plasma concentrations for up to three days.

Oxybutynin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Dry mouth: reduced salivary secretion causing thirst.
• Constipation: slowed gastrointestinal motility leading to hard stools.
• Blurred vision: transient visual disturbances due to ocular anticholinergic effect.
• Skin irritation at patch site: redness or itching where the patch is applied.

Serious or Rare Side Effects

• Urinary retention: difficulty emptying bladder, may require catheterization.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Hepatic dysfunction: elevated liver enzymes indicating liver injury.

Before initiating therapy, consider the following precautions.

• Assess renal and hepatic function: adjust therapy if significant impairment is present.
• Review cardiac history: monitor for tachycardia or arrhythmias during treatment.
• Evaluate for narrow‑angle glaucoma: anticholinergic effects may worsen intra‑ocular pressure.
• Avoid use in patients with urinary retention: risk of worsening bladder emptying.
• Store at room temperature: keep in original pouch, protect from moisture and direct heat.

Oxybutynin may interact with other medications; review patient medication lists.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase oxybutynin plasma levels.
• Other anticholinergic agents (e.g., atropine, scopolamine): additive anticholinergic burden.
• Narrow‑angle glaucoma medications (e.g., pilocarpine): may exacerbate ocular pressure.

Moderate Interactions (Monitor Closely)

• Antihistamines (e.g., diphenhydramine): may enhance dry‑mouth and constipation.
• Beta‑blockers (e.g., propranolol): potential increase in heart rate.
• Diuretics (e.g., furosemide): may aggravate dehydration and electrolyte imbalance.